KORSCH introduces next-generation mid-range tablet press
X 3 Tablet Press incorporates production capabilities and versatility traditionally limited to large-scale production machines.
KORSCH is introducing a mid-range tablet press incorporating innovative features previously available only on large production machines.
The new X 3 Tablet Press is a single-sided rotary press that redefines this market segment, with flexible technology and a new approach to architectural and ergonomic design.
Suitable for product development, scale-up, clinical production, mid-range production and continuous manufacturing, the next-generation X 3 Tablet Press is available in two models. The X 3 SFP is a dedicated single-layer press capable of 266,400 tablets/hour, whereas the X 3 MFP offers flexible single-layer (266,400 tablets/hour) and bi-layer (133,200 tablets/hour) production capability.
The X 3 incorporates a flexible manufacturing experience atypical for its size, with an integrated electrical cabinet, torque drive, fully sealed design, and unsurpassed accessibility for cleaning, changeovers and maintenance.
Installation options include a conventional in-room layout, through-the-wall mounting, and a portable equipment platform. The X 3 offers a range of product containment configurations, including OEB 3, as well as OEB 4/5 with full wash-in-place and high-containment execution.
In addition, the X 3's exchangeable turret technology allows for an extremely fast transition between products, and the ability to produce a tablet of any size and shape.
For mid-range manufacturing, the X 3 offers a long filling length and large, variable-speed power feeder for precision die filling at extremely high speeds. For changeovers, superior compression zone access, smooth surfaces, and minimal fast change parts yield an expedited process for maximized machine uptime.
The unique KORSCH machine structure provides excellent visibility and unlimited access to the compression zone for streamlined changeover and turret exchange. It is a fully sealed machine with no heat transfer to the compression zone of the press, or to the compression room. This closed design also eliminates potential contamination in the machine base or electrical cabinet, and further expedites the changeover process.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.